Johnson & Johnson Partners with Vibalogics on Development of Lead COVID-19 Vaccine Candidate
By HospiMedica International staff writers Posted on 20 May 2020 |
Image: Johnson & Johnson Partners with Vibalogics on Development of Lead COVID-19 Vaccine Candidate (Photo courtesy of Johnson & Johnson)
Vibalogics GmbH (Cuxhaven, Germany) will manufacture additional clinical trial material for the lead COVID-19 vaccine candidate currently in development by Johnson & Johnson’s (New Brunswick, NJ, USA) Janssen Pharmaceutical Companies (Beerse, Belgium).
Vibalogics, a global contract development and manufacturing organization that specializes in the production of virotherapy products, is contracted to manufacture multiple batches, which will result in many thousands of doses of an investigational COVID-19 vaccine candidate. Vibalogics will carry out the production at its GMP-accredited facility in Germany where it has recently invested in new equipment to handle larger clinical batches, including a new filling line capable of filling and labeling more than 30,000 vials per batch. Vibalogics is also set to establish a commercial facility in North America for oncolytic viruses, viral vectors for gene therapy approaches and viral vector vaccines in the near future.
“This has been a tremendous challenge for everyone at Vibalogics, but one which the entire team has embraced as an opportunity to use our experience and expertise in the global fight against COVID-19,” said Stefan Beyer, managing director and CEO of Vibalogics. “The business has reacted quickly and efficiently to accommodate this request. With the devotion of our team, and understanding from our customers, we have successfully managed to fulfill this new requirement alongside all of our existing business commitments.”
“This is a fantastic opportunity for the business and our employees to strengthen our position as a global leader in virotherapy manufacturing whilst also providing a key service to our valued customer in its mission to combat the SARS-CoV-2 virus,” added Beyer. “This endeavor is testament to our long-standing and productive partnership with this company, who have shown great trust in our flexible approach, expertise and ability to deliver on time.”
Related Links:
Johnson & Johnson
Janssen Pharmaceutical Companies
Vibalogics GmbH
Vibalogics, a global contract development and manufacturing organization that specializes in the production of virotherapy products, is contracted to manufacture multiple batches, which will result in many thousands of doses of an investigational COVID-19 vaccine candidate. Vibalogics will carry out the production at its GMP-accredited facility in Germany where it has recently invested in new equipment to handle larger clinical batches, including a new filling line capable of filling and labeling more than 30,000 vials per batch. Vibalogics is also set to establish a commercial facility in North America for oncolytic viruses, viral vectors for gene therapy approaches and viral vector vaccines in the near future.
“This has been a tremendous challenge for everyone at Vibalogics, but one which the entire team has embraced as an opportunity to use our experience and expertise in the global fight against COVID-19,” said Stefan Beyer, managing director and CEO of Vibalogics. “The business has reacted quickly and efficiently to accommodate this request. With the devotion of our team, and understanding from our customers, we have successfully managed to fulfill this new requirement alongside all of our existing business commitments.”
“This is a fantastic opportunity for the business and our employees to strengthen our position as a global leader in virotherapy manufacturing whilst also providing a key service to our valued customer in its mission to combat the SARS-CoV-2 virus,” added Beyer. “This endeavor is testament to our long-standing and productive partnership with this company, who have shown great trust in our flexible approach, expertise and ability to deliver on time.”
Related Links:
Johnson & Johnson
Janssen Pharmaceutical Companies
Vibalogics GmbH
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans